However, it is important to note that gilteritinib, midostaurin and crenolanib killed over 50% of mutant CBL‐expressing cells, compared with around 70%‐80% of wt FLT3/wt CBL‐expressing AML or mutant FLT3/wt CBL‐expressing AML. This evidence concerns the gene CBL and acute myeloid leukemia.